Antiplatelet Therapy Just Got Personal.
Approximately 81 million Americans have one or more types of cardiovascular disease1 and an additional 15 million people suffer from neurovascular disease worldwide2. Antiplatelet agents (such as aspirin, clopidogrel and prasugrel) are widely prescribed in patients with acute coronary syndrome (ACS) to prevent heart attacks, strokes and other potentially life-threatening cardiovascular events:
- 50 million Americans are on chronic aspirin therapy3
- Over 29 million patients are on Plavix®4 and over
6.5 million new prescriptions are written annually for Plavix,
making it the second largest selling drug worldwide.5
Studies show that patients Do Not respond equally to antiplatelet therapy.
- Up to 1/3 of patients on antiplatelet medications may not respond adequately to antiplatelet medications. 6
- Patients who are not responding adequately to their antiplatelet medications may be at significantly higher risk of ischemic events and death.7
Therefore, early assessment of your patient’s platelet response to antiplatelet therapy is crucial to improving patient care.
Assessing how patients respond to their antiplatelet therapy should be easy.
it is.
